ORIGINAL ARTICLE
Influence of TNF-α promoter variability on stage and grade in individuals with colorectal cancer
More details
Hide details
Submission date: 2017-10-11
Final revision date: 2017-12-26
Acceptance date: 2018-01-06
Publication date: 2018-07-06
Pol J Pathol 2018;69(2):150-156
KEYWORDS
TOPICS
ABSTRACT
Carcinogenesis is a multistep process in which inflammation plays an important role. Tumour necrosis factor a (TNF-α) is a cytokine that plays a major role in inflammation. Activity of the TNF cytokine family could influence progression of colorectal cancer (CRC). The aim of the study was to establish an association between TNF-α promoter variability and stage/grade in individuals with sporadic CRC. The study included 152 CRC patients and 107 healthy volunteers. Four single nucleotide polymorphisms (rs361525, rs1800629, rs1799724, and rs1799964) located at the promoter of TNFA gene were genotyped using commercially available TaqMan allelic discrimination assays by real-time PCR. CRC stage was described on the basis of preoperative imaging studies and postoperative histopathological report. The grade was described on the basis postoperative pathological examination of the specimen. In the case of rs361525, there was a statistically significant association with M-score (p = 0.0209). Rs361525 has significant association with tumour grade (p = 0.0260). We failed to demonstrate significant association between the other 3 SNPs and cancer grade. Rs361525 potentially could be under consideration when the survival rate and prognosis is assessed.
REFERENCES (27)
1.
Torre LA, Siegel RL, Ward EM, Jemal A. Global cancer incidence and mortality rates and trends − an update. Cancer Epidemiol Biomarkers Prev 2016; 25: 16-27.
2.
Zhang K, Chen Y, Huang X, et al. Expression and clinical significance of cytochrome c oxidase subunit IV in colorectal cancer patients. Arch Med Sci 2016; 12: 68-77.
3.
Coussens LM, Werb Z. Inflammation and cancer. Nature 2002; 420: 860-867.
4.
Balkwill F. TNF-alpha in promotion and progression of cancer. Cancer Metastasis Rev 2006; 25: 409-416.
5.
Marszałek A, Szylberg L, Wiśniewska E, et al. Impact of COX-2,.
6.
IL-1β, TNF-α, IL-4 and IL-10 on the process of carcinogenesis in the large bowel. Pol J Pathol 2012; 63: 221-227.
7.
Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001; 104: 487-501.
8.
Lewandowska M, Hybiak J, Domagala W. Concordance of KRAS mutation status between luminal and peripheral regions of primary colorectal cancer. A laser-capture microdissection-based study. Pol J Pathol 2016; 67: 13-18.
9.
Waters JP, Pober JS, Bradley JR. Tumour necrosis factor and cancer. J Pathol 2013; 230: 241-248.
10.
Szlosarek P, Charles KA, Balkwill FR. Tumour necrosis factor-alpha as a tumour promoter. Eur J Cancer 2006; 42: 745-750.
11.
Edge S, Byrd DR, Compton CC, et al. (eds.), AJCC Cancer Staging Handbook 2010. Springer-Verlag, New York 2010.
12.
Stanilov N, Mitevac L, Dobrevac Z, Stanilova S. Colorectal cancer severity and survival in correlation with tumour necrosis factor-alpha. Biotechnol Biotechnol Equip 2014; 28, 911-917.
13.
Balkwill F. Tumor necrosis factor or tumor promoting factor? Cytokine Growth Factor Rev 2002; 13: 135-141.
14.
Machado JC, Figueiredo C, Canedo P, et al. A proinflammatory genetic profile increases the risk for chronic atrophic gastritis and gastric carcinoma. Gastroenterology 2003; 125: 364-371.
15.
Csiszár A, Szentes T, Haraszti B, et al. The pattern of cytokine gene expression in human colorectal carcinoma. Pathol Oncol Res 2004; 10: 109-116.
16.
Al Obeed OA, Alkhayal KA, Al Sheikh A, et al. Increased expression of tumor necrosis factor-α is associated with advanced colorectal cancer stages. World J Gastroenterol 2014; 20: 18390-18396.
17.
Zhou C, Nitschke AM, Xiong W, et al. Proteomic analysis of tumor necrosis factor-α resistant human breast cancer cells reveals a MEK5/Erk5-mediated epithelial-mesenchymal transition phenotype. Breast Cancer Res 2008; 10: 101-105.
18.
Sousa H, Oliveira S, Santos AM, et al. Tumour necrosis factor alpha 308 G/A is a risk marker for the progression from high-grade lesions to invasive cervical cancer. Tumour Biol 2014; 35: 2561-2564.
19.
Kroeger KM, Carville KS, Abraham LJ. The α-308 tumor necrosis factor-alpha promoter polymorphism effects transcription. Mol Immunol 1997; 34: 391-399.
20.
Wilson AG, Symons JA, McDowell TL, et al. Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci U S A 1997; 94: 3195-3199.
21.
Korobeinikova E, Myrzaliyeva D, Ugenskiene R, et al. The prognostic value of IL10 and TNF alpha functional polymorphisms in premenopausal early-stage breast cancer patients. BMC Genet 2015; 26: 16-70.
22.
Hamadien MA, Khan Z, Vaali-Mohammed MA, et al. Polymorphisms of tumor necrosis factor alpha in Middle Eastern population with colorectal cancer. Tumor Biol 2016; 37: 5529-5537.
23.
Min L, Chen D, Qu L, et al. Tumor necrosis factor-a polymorphisms and colorectal cancer risk: a meta-analysis. PLoS One 2014; 9: e85187.
24.
Li M, You Q, Wang X. Association between polymorphism of the tumor necrosis factor alpha-308 gene promoter and colon cancer in the Chinese population. Genet Test Mol Biomarkers 2011; 15: 743-747.
25.
Theodoropoulos G, Papaconstantinou I, Felekouras E. Relation between common polymorphisms in genes related to inflammatory response and colorectal cancer. World J Gastroenterol 2006; 12: 5037-5043.
26.
Guo XF, Wang J, Yu SJ. TNF-α-308 polymorphism and risk of digestive system cancers: a meta-analysis. World J Gastroenterol 2013; 19: 9461-9471.
27.
Rattray NJW, Charkoftaki G, Rattray Z, et al. Environmental influences in the etiology of colorectal cancer: the premise of metabolomics. Curr Pharmacol Rep 2017; 3: 114-125.